Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0041228
Disease: African Trypanosomiasis
African Trypanosomiasis
0.010 Biomarker disease BEFREE <i>Trypanosoma brucei</i> causes African trypanosomiasis and contains three full-length oligosaccharyltransferase (OST) genes; two of which, <i>Tb</i>STT3A and <i>Tb</i>STT3B, are expressed in the bloodstream form of the parasite. 28928222 2017
CUI: C1857277
Disease: Donnai-Barrow syndrome
Donnai-Barrow syndrome
0.010 GeneticVariation disease BEFREE Donnai-Barrow syndrome (DBS/FOAR) in a child with a homozygous LRP2 mutation due to complete chromosome 2 paternal isodisomy. 18553518 2008
CUI: C0178417
Disease: Anhedonia
Anhedonia
0.010 Biomarker disease BEFREE Anhedonia reduction observed during the first 30days after initiating the stimulation persisted in the assessment six months after implantation of the DBS. 28320164 2017
CUI: C0021051
Disease: Immunologic Deficiency Syndromes
Immunologic Deficiency Syndromes
0.010 Biomarker group BEFREE DBS could be used as an alternative for DPS depending on HIV RNA cutoffs for virological failure. 19193835 2009
CUI: C0030193
Disease: Pain
Pain
0.030 Biomarker phenotype BEFREE MCF2L regulates a nerve growth factor (NGF), and treatment with a humanized monoclonal antibody against NGF is associated with reduction in pain and improvement in function for knee OA patients. 21871595 2011
CUI: C0029408
Disease: Degenerative polyarthritis
Degenerative polyarthritis
0.130 Biomarker disease BEFREE MCF2L regulates a nerve growth factor (NGF), and treatment with a humanized monoclonal antibody against NGF is associated with reduction in pain and improvement in function for knee OA patients. 21871595 2011
CUI: C0029408
Disease: Degenerative polyarthritis
Degenerative polyarthritis
0.130 Biomarker disease BEFREE MCF2L is involved in neurotrophin mediated regulation of cell motility in the peripheral nervous system, and thus potentially implicated in nociception in OA. 22178404 2012
CUI: C0029456
Disease: Osteoporosis
Osteoporosis
0.020 Biomarker disease BEFREE OST index ≤2 predicted osteoporosis with a sensitivity of 95.7% and a specificity of 33.6% and an area under the curve for a receiver operating characteristic curve of 0.702. 27210803 2018
CUI: C0013421
Disease: Dystonia
Dystonia
0.100 Biomarker phenotype BEFREE DBS effects on dystonia severity were variable but overall marginally effective, with a mean improvement of 7.9% (p = 0.39) at 1-year follow-up and 16.7% (p = 0.46) at last follow-up (mean 47.3 ± 19.9 months after surgery). 27743838 2017
CUI: C0393593
Disease: Dystonia Disorders
Dystonia Disorders
0.100 Biomarker group BEFREE DBS effects on dystonia severity were variable but overall marginally effective, with a mean improvement of 7.9% (p = 0.39) at 1-year follow-up and 16.7% (p = 0.46) at last follow-up (mean 47.3 ± 19.9 months after surgery). 27743838 2017
CUI: C0026650
Disease: Movement Disorders
Movement Disorders
0.050 Biomarker group BEFREE DBS is a surgical method of choice for various movement disorders, especially for Parkinson's disease (PD). 28320164 2017
CUI: C0030567
Disease: Parkinson Disease
Parkinson Disease
0.100 Biomarker disease BEFREE DBS is a surgical method of choice for various movement disorders, especially for Parkinson's disease (PD). 28320164 2017
CUI: C0270736
Disease: Essential Tremor
Essential Tremor
0.100 Biomarker disease BEFREE DBS is initially used for treatment of essential tremor and Parkinson's disease in adults. 29797064 2018
CUI: C0030567
Disease: Parkinson Disease
Parkinson Disease
0.100 Biomarker disease BEFREE DBS is initially used for treatment of essential tremor and Parkinson's disease in adults. 29797064 2018
CUI: C0026650
Disease: Movement Disorders
Movement Disorders
0.050 Biomarker group BEFREE DBS has been trialed to treat related movement disorders, particularly dystonia. 30633810 2019
CUI: C0013421
Disease: Dystonia
Dystonia
0.100 Biomarker phenotype BEFREE DBS has been trialed to treat related movement disorders, particularly dystonia. 30633810 2019
CUI: C0393593
Disease: Dystonia Disorders
Dystonia Disorders
0.100 Biomarker group BEFREE DBS has been trialed to treat related movement disorders, particularly dystonia. 30633810 2019
CUI: C4049471
Disease: End stage Parkinson's disease
End stage Parkinson's disease
0.010 Biomarker disease BEFREE DBS generator replacement surgery is low risk, even in patients who have end-stage PD. 31059853 2019
CUI: C0028259
Disease: Nodule
Nodule
0.010 AlteredExpression phenotype BEFREE A combination of MTA and OST upregulated odontogenic differentiation-associated gene expression and calcium nodule mineralization in hDPCs compared with MTA alone. 29061354 2017
CUI: C0011265
Disease: Presenile dementia
Presenile dementia
0.040 Biomarker disease BEFREE A comprehensive knowledge of the white matter anatomy of the mammillothalamic and mammillotegmental tracts is crucial since they have emerged as new DBS targets in the treatment of various disorders including dementia and epilepsy. 29129763 2018
CUI: C0497327
Disease: Dementia
Dementia
0.040 Biomarker disease BEFREE A comprehensive knowledge of the white matter anatomy of the mammillothalamic and mammillotegmental tracts is crucial since they have emerged as new DBS targets in the treatment of various disorders including dementia and epilepsy. 29129763 2018
CUI: C0014544
Disease: Epilepsy
Epilepsy
0.060 Biomarker disease BEFREE A comprehensive knowledge of the white matter anatomy of the mammillothalamic and mammillotegmental tracts is crucial since they have emerged as new DBS targets in the treatment of various disorders including dementia and epilepsy. 29129763 2018
CUI: C0013421
Disease: Dystonia
Dystonia
0.100 Biomarker phenotype BEFREE A dramatic and long-lasting response to DBS is characteristic of DYT-KMT2B dystonia. 31216378 2019
CUI: C0393593
Disease: Dystonia Disorders
Dystonia Disorders
0.100 Biomarker group BEFREE A dramatic and long-lasting response to DBS is characteristic of DYT-KMT2B dystonia. 31216378 2019
CUI: C0426980
Disease: Motor symptoms
Motor symptoms
0.100 Biomarker phenotype BEFREE A dramatic improvement in motor symptoms was equally observed in both groups of patients after DBS. 31028845 2019